Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 5526

Biosimilar Red Tape Elimination Act

House Committee Reviews Bill to Grant Biosimilars Automatic Interchangeable Status at Approval

Legislative Progress

House
Senate
President
Law

Key Points

  • Would make most biosimilar medicines automatically interchangeable with the original biologic once approved, instead of needing a separate extra decision.
  • Sets a switch-over date 60 days after the bill becomes law. Biosimilars approved before then become interchangeable on that date.
  • Keeps existing “first interchangeable” exclusivity protections for certain older products, so some automatic switching could be delayed until that period ends.
  • Requires the Health Department to update and revise its public guidance within 18 months so drug companies know what data to submit.
  • Does not change the basic safety and effectiveness standard for biosimilars; it mainly changes how interchangeability is handled and documented.
HealthcarePrescription DrugsConsumer Protection

Impact Analysis

Personal Impact

How this policy affects specific groups of people

Mixed Impacts(3)
Medicare
Neutral
Medicaid
Neutral
Retiree
Neutral
Positive Impacts(2)
Chronic Illness
Helps
Disability Benefits
Helps

Milestones

2 milestones2 actions
Sep 19, 2025House

Referred to the House Committee on Energy and Commerce.

Sep 19, 2025

Introduced in House

The bill was officially filed and given a number. It now enters the legislative queue.

Votes

No votes have been recorded for this legislation yet.

Source Information

Document Type

Congressional Bill

Official Title

Biosimilar Red Tape Elimination Act

Bill NumberHR 5526
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the House Committee on Energy and Commerce.

Sponsor

Cosponsors

(4)
D: 3R: 1

Analysis generated by AI. Always verify with official sources.